Arquivos Brasileiros de Endocrinologia & Metabologia
versão impressa ISSN 0004-2730
KULAK JUNIOR, Jaime; KULAK, Carolina Aguiar Moreira e TAYLOR, Hugh S.. SERMs in the prevention and treatment of postmenopausal osteoporosis: an update. Arq Bras Endocrinol Metab [online]. 2010, vol.54, n.2, pp. 200-205. ISSN 0004-2730. http://dx.doi.org/10.1590/S0004-27302010000200016.
Selective estrogen receptor modulators (SERMs) have the ability to bind the estrogen receptor (ER) and are known to confer ER agonist or antagonist effects depending on the target tissue. A number of newer SERMs, including bazedoxifene, lasofoxifene and ospemifene, are currently under clinical development for the prevention and treatment of postmenopausal osteoporosis and for other indications. Although the possibility of developing a single agent that has all of the desired characteristics of an ideal SERM seems to be unlikely, progress in the clinical development of SERMs targeted to the ER suggests that these newer compounds may have attributes that represent an improvement relative to existing SERMs. A new approach to menopausal therapy is the tissue selective estrogen complex or the pairing of a selective estrogen receptor modulator with estrogens. Further investigation will help to clarify relative benefits/risks of novel SERMs in development within specific indications.
Palavras-chave : Selective estrogen receptor modulator (SERM); menopause; estrogens; osteoporosis; tissue selective estrogen complex (TSEC).